Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Erasca, Inc. securities between January 14, 2025 and April 26, 2026. The lawsuit alleges that Erasca failed to disclose it was at risk of violating patent and trade secret protections, specifically that ERAS-0015’s preclinical data was based on improper comparisons to Revolution Medicines and placed Erasca at risk of infringement. On April 27, 2026, Erasca disclosed it had received a letter from RevMed’s legal counsel alleging patent infringement and trade secret misappropriation, causing Erasca’s stock price to fall from $21.49 per share on April 24, 2026, to $19.15 per share on April 27, 2026. Shareholders who wish to serve as lead plaintiff must submit their papers to the court by August 10, 2026.
Erasca IncClass action lawsuit alleges failure to disclose patent infringement risk; stock price dropped on disclosure of RevMed's legal letter.
Revolution Medicines IncRevMed is the plaintiff alleging patent infringement and trade secret misappropriation against Erasca, which could benefit RevMed.